

![]() |
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient |
|
Authors | ![]() | |
Published in | Antiviral therapy. 2019, vol. 24, no. 8, p. 581-587 | |
Abstract | Neuraminidase (NA) inhibitors (NAIs), including oseltamivir and zanamivir, play an important therapeutic role against influenza infections in immunocompromised patients. In such settings, however, NAI therapy may lead to the emergence of resistance involving mutations within the influenza surface genes. The aim of this study was to investigate the evolution of NA and haemagglutinin (HA) genes of influenza A(H1N1)pdm09 virus in an immunocompromised patient receiving oseltamivir then zanamivir therapies. | |
Keywords | Aged — Antiviral Agents/administration & dosage/pharmacology/therapeutic use — Drug Resistance, Multiple, Viral — Enzyme Inhibitors/administration & dosage/pharmacology/therapeutic use — Hematopoietic Stem Cell Transplantation — Humans — Immunocompromised Host — Influenza A Virus, H1N1 Subtype/drug effects/genetics — Influenza, Human/drug therapy/virology — Male — Neuraminidase/antagonists & inhibitors — Oseltamivir/administration & dosage/pharmacology/therapeutic use — Transplant Recipients — Zanamivir/administration & dosage/pharmacology/therapeutic use | |
Identifiers | DOI: 10.3851/IMP3344 PMID: 32031540 | |
Full text | ||
Structures | ||
Research groups | Groupe Laurent Kaiser (virologie clinique) (668) Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982) | |
Citation (ISO format) | ABED, Yacine et al. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient. In: Antiviral Therapy, 2019, vol. 24, n° 8, p. 581-587. doi: 10.3851/IMP3344 https://archive-ouverte.unige.ch/unige:147186 |